Last reviewed · How we verify
The Efficacy, Safety, and Tolerability of Pegaptanib Sodium in Filipino Patients With Neovascular Age-related Macular Degeneration: A Post Marketing Surveillance Study.
An open label, non-comparative, multicenter, non-interventional, post marketing surveillance study to evaluate the overall safety and tolerability of pegaptanib sodium(Macugen) in the treatment of Filipino patients with neovascular age-related macular degeneration based on incidence of adverse events and to evaluate the efficacy based on visual acuity, and the patient's and physician's overall satisfaction with tolerability and efficacy.
Details
| Lead sponsor | Pfizer |
|---|---|
| Status | WITHDRAWN |
| Start date | 2008-02 |
| Completion | 2009-05 |
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
- Macugen
Primary outcomes
- Incidence of adverse events and serious adverse events — 12 months